Role of immunotherapy in bladder cancer: past, present and future Sabeeh-ur-Rehman ButtLaeeq Malik Review Article 24 January 2018 Pages: 629 - 645
PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer Robert D. MorganAndrew R. ClampGordon C. Jayson Review Article Open access 20 February 2018 Pages: 647 - 658
Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer Anthony B. El-KhoueiryJohn SarantopoulosBassel F. El-Rayes Original Article 21 February 2018 Pages: 659 - 670
Long non-coding RNA TUSC7 inhibits temozolomide resistance by targeting miR-10a in glioblastoma Chao ShangWei TangYang Hong Original Article 03 February 2018 Pages: 671 - 678
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153 David WaterhouseLeora HornNivedita Aanur Original Article 13 February 2018 Pages: 679 - 686
YSA-conjugated mesoporous silica nanoparticles effectively target EphA2-overexpressing breast cancer cells Zhi LiuZijian TaoJiandong Wang Original Article 01 February 2018 Pages: 687 - 695
Incidence of leukopenia and thrombocytopenia with cisplatin plus mitomycin-c versus melphalan in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) Hakeam A. HakeamAmal ArabTarek Amin Original Article 10 February 2018 Pages: 697 - 704
Electrophilic derivatives of omega-3 fatty acids counteract lung cancer cell growth Liboria SienaChiara CipollinaElisabetta Pace Original Article 12 February 2018 Pages: 705 - 716
Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells Jie CuiMin-Cong WangLi-Ping Song Original Article 26 February 2018 Pages: 717 - 726
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors Frederik MarméCarlos Gomez-RocaJan Eucker Original Article 21 February 2018 Pages: 727 - 737
FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma Noboru NakaigawaKeiichi KondoMasahiro Yao Original Article 20 February 2018 Pages: 739 - 744
Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro Valentina CitiMarzia Del ReRomano Danesi Original Article 23 February 2018 Pages: 745 - 754
Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC) Takahiro NakayamaYasuaki SagaraShinzaburo Noguchi Original Article Open access 21 February 2018 Pages: 755 - 762
Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model Andrea GruberMartin CzejkaAzra Sahmanovic Hrgovcic Original Article Open access 16 February 2018 Pages: 763 - 771
Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice Concetta PanebiancoKaarel AdambergValerio Pazienza Original Article 22 February 2018 Pages: 773 - 782
Ibrutinib brain distribution: a preclinical study Lauriane GoldwirtKevin BeccariaSamia Mourah Short Communication 23 February 2018 Pages: 783 - 789
A novel way to manage trastuzumab cardiotoxicity Diaddin HamdanFrançois DarrouzainGuilhem Bousquet Short Communication 01 March 2018 Pages: 791 - 796